High density lipoproteins (HDLs) play a role in two processes that include the amelioration of atheroma formation and the centripetal flow of cholesterol from the extrahepatic organs to the liver. This study tests the hypothesis that the flow of sterol from the peripheral organs to the liver is dependent upon circulating HDL concentrations. Transgenic C57BL/6 mice were used that expressed variable amounts of simian cholesteryl ester-transfer protein (CETP). 
In all species, the major net flux of cholesterol in the body involves the movement of sterol from the extrahepatic organs to the liver. In a primate such as the cynomolgus monkey (and, very likely, the human), the magnitude of this flux equals [10] [11] mg of sterol per day per kg of body weight (1) . However, this flux increases dramatically in animals of lower body weight and higher basal metabolic activity, reaching approximately 100 mg/day per kg in small mammals such as the mouse (2) . Since these peripheral organs take up little cholesterol carried in low density lipoproteins (LDL-C) from the plasma, most of this net flow of sterol consists of cholesterol that is newly synthesized in these same tissues (1, 3, 4) . In the monkey and mouse, for example, de novo synthesis accounts for 77 and 95%, respectively, of the cholesterol involved in this centripetal sterol flux (1, 2) . There is abundant experimental data supporting the concept that one of the major functions of high density lipoproteins (HDLs) is to facilitate this constant movement of cholesterol from the extrahepatic tissues to the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
liver (for reviews, see refs. 5 and 6). However, there is virtually no quantitative data dealing with the fundamental question of whether the magnitude of this centripetal flux is dictated by events within the cells of the peripheral organs or, alternatively, is determined by the concentration of HDL circulating in the plasma compartment.
In addition to this normal physiological function, the HDL particle has also been implicated as an important determinant of the pathological process of atheroma formation. The data that support this association are of two types. First, in epidemiological studies the concentration of plasma total cholesterol (in general) and of LDL-C (in particular) have been shown to vary directly with the incidence of coronary artery disease (7) (8) (9) . In contrast, the concentration of cholesterol carried in HDL (HDL-C) varies inversely with such disease (10) (11) (12) (13) . Second, this role of HDL in preventing atherosclerosis has been demonstrated more directly in recent studies using a variety of transgenic mice. Lowering the concentration of HDL-C by overexpressing cholesteryl ester-transfer protein (CETP), for example, leads to more severe atherosclerosis in cholesterol-fed mice (14) . Similarly, mice lacking apolipoprotein (apo)E develop striking atherosclerosis (15, 16) , but this process is ameliorated by overexpressing apoAI and thereby raising the steady-state concentration of HDL-C (17, 18) . Thus, these varied data strongly suggest that the severity of the atherosclerotic process is, in some manner, inversely related to the steady-state concentration of HDL-C.
Many of the specific processes involved in the centripetal flow of sterol from the interior of each extrahepatic cell to the liver are now known. In nearly all of these tissues, most cholesterol comes from continuous synthesis on the endoplasmic reticulum (1, 3, 4, 19, 20) , and this unesterified sterol may then move to the cell membrane by vesicular transport through the Golgi apparatus (21) . Indeed, direct observations have shown progressive sterol enrichment of the stacked cisternae between the endoplasmic reticulum and the plasma membrane (22) . This cholesterol is then presumably inserted into the plasma membrane where it is concentrated in structures like caveolae and glycosphingolipid-enriched complexes (23) (24) (25) . In the presence of an appropriate acceptor such as apoAI or apoE, cholesterol readily desorbs from the external leaflet of the plasma membrane and is esterified to cholesteryl ester by the enzyme lecithin/cholesterol acyltransferase (6, (26) (27) (28) (2, 31) . The major organs were removed, weighed, and saponified. The remaining carcass, which was composed primarily of skeleton, muscle, and adipose tissue, was also saponified and the content of total cholesterol determined. The levels of apoAI and CETP in the plasma of these animals were determined as previously described (29, 32 LDL-C Transport into the Extrahepatic Tissues in Vivo. All LDL-C transport measurements were undertaken using homologous LDL preparations because lipoproteins from other species give transport rates that vary from those obtained with mouse LDL (2) . Mouse plasma was harvested from both male and female LDL receptor knockout animals that had been maintained on a low cholesterol diet (2) , and an LDL fraction was isolated between the densities of 1.020 and 1.055 g/ml. The lipoproteins in this fraction were labeled with either 1251-tyramine cellobiose or 1311 (1, 35) . These radiolabeled lipoprotein fractions were then applied to a slurry gel composed of Geon-Pevikon and electrophoresed to separate the LDL from the small amounts of apoE-containing HDL present in the preparations (36, 37 (29, 30, 32) .
The concentration of cholesterol in each of the extrahepatic organs was essentially constant in these animals between the ages of 2 and 4 months. Fig. 1 summarizes these concentrations in the 3-month-old mice used in all subsequent experiments. In the control animals, the adrenal gland and brain had the highest concentrations of cholesterol (20.1 ± 1.6 and 15.0 ± 0.3 mg/g, respectively), whereas the concentration in all of the other peripheral organs was <5.0 mg/g. In the CETP+ mice the concentration of cholesterol was virtually identical to the control mice in all of the extrahepatic organs except the adrenal gland, where it equaled only 6.6 ± 0.9 mg/g. This lower level of tissue sterol presumably reflected the lower concentration of circulating HDL-C in these animals because the rodent is known to have a HDL-specific cholesterol uptake process in the adrenal gland (39) (40) (41) . While not shown in Fig.  1 , the concentration of hepatic cholesterol was also the same in the CETPC (2.1 ± 0.1 mg/g) and CETP+ (2.2 ± 0.1 mg/g) mice. From these concentration values and the weights of the individual organs, it was calculated that the total extrahepatic cholesterol pool equaled 1.84 ± 0.04 and 1.73 ± 0.04 g per kg body weight, respectively, in the control and CETP+ animals. However, the sterol in the adrenal gland and testes presumably was largely used for hormone synthesis and was not being transported to the liver. When these two small subpools of sterol were subtracted from the total peripheral pool, the mass of the cholesterol in the remaining extrahepatic organs equaled 1.82 ± 0.04 and 1.70 ± 0.04 g per kg body weight, respectively. Thus, the steady-state pool of cholesterol in the extrahepatic organs contributing sterol to the liver was essentially the same in the presence and absence of CETP activity in the plasma.
Since the most important source for cholesterol turnover in these extrahepatic pools was de novo sterol synthesis, the rates of [3H]water incorporation into digitonin-precipitable sterols were next measured in vivo in these same organs. As summarized in Fig. 2A , the highest rates of synthesis per g of tissue in the extrahepatic organs of the CETPC animals were found in the adrenal gland, small bowel, stomach, and colon. Lesser rates were seen in the other organs. A similar profile of synthetic activity was found in the CETP+ mice, although in a few tissues the rate of synthesis was either significantly (P < 0.05) higher-e.g., small bowel and colon-or significantly lower-e.g., spleen and lung-than in the control mice. However, when the rates of cholesterol synthesis were calculated in the whole organs (Fig. 2B) Fig. 3A , of all of the extrahepatic tissues only the adrenal gland manifested a fairly high rate of LDL clearance (115 ± 14 A,l/h per g) in the CETPC animals, and this rate was nearly 3-fold higher (300 ± 101 ,l/h per g) in the CETP+ mice. In contrast to this endocrine tissue, however, the rates of LDL clearance in all of the remaining extrahepatic organs were much lower and essentially the same in the two groups of animals. When organ weights were taken into consideration, as shown in Fig. 3B , it was apparent that very little LDL transport occurred into any extrahepatic organ. After subtracting the small amounts of LDL cleared by the adrenal gland and testes, LDL clearance in all of the remaining extrahepatic organs equaled only 79 ± 5 ,l/h in the control animals and 90 ± 14 Al/h in the CETP+ mice. From these values and the concentration of LDL-C found in the plasma (Table 1) into their extrahepatic tissue compartments an amount of LDL-C equal to only 0.2% of the steady-state cholesterol pool present in these organs.
Because the concentration of cholesterol in the organs of the extrahepatic compartment did not change, the rate of centripetal cholesterol flux from the peripheral tissues to the liver could be calculated as the sum of the rates of sterol synthesis and LDL-C uptake in these organs. These rates, in turn, could be plotted as a function of the steady-state concentration of HDL-C found in the same animals, as shown in Fig. 4 
DISCUSSION
These studies provide strong evidence that the molecular processes that are involved in the regulation of cholesterol movement from the interior of cells in the extrahepatic organs to the liver are very different from those that are associated with interaction of the HDL particle with the arterial wall. In the mouse model used in these experiments, lowering the steady-state concentration of HDL-C by expressing CETP resulted in more severe atherosclerosis (14) , yet there was a change in the rate of neither cholesterol synthesis (Fig. 2) nor LDL-C uptake (Fig. 3) in the extrahepatic organs nor an alteration in the flow of sterol from these tissues to the liver (Fig. 4) . A similar situation has been reported in another mouse model where deletion of apoE was also associated with reduced concentrations of circulating HDL-C and atheroma formation (16, 42) , but again, the flow of cholesterol from the extrahepatic organs to the liver was essentially the same in the control mice (84 ± 3 mg/day per kg) and in the homozygous knockout animals (81 ± 2 mg/day per kg) (43) . Thus If, as these findings suggest, the magnitude of net sterol flux from the extrahepatic organs is independent of events in the vascular space, then the rate-determining step for this process must reside within the cells of the tissues themselves. This possibility is supported by observations in a third mouse model. In the normal animal where >90% of LDL-C is removed from the plasma by the liver, little LDL-C normally reaches the peripheral organs (Fig. 3) . However, when the LDL receptor activity responsible for this hepatic clearance is deleted, the rate of LDL-C uptake by receptor-independent mechanisms in the peripheral organs increases from 5 mg/day per kg to 25 mg/day per kg. Under these conditions, the centripetal flux of cholesterol from these organs to the liver does increase, from 106 mg/day per kg in the control mice to 133 mg/day per kg in the receptor negative animals (2) . While this extreme example suggests that some process within the cells of the extrahepatic organs does dictate overall centripetal flux, under more physiological conditions it is not known whether the velocity of this process is determined by rates of vesicular transport or some component of plasma membrane cholesterol translocation. The elucidation of which of these steps is involved is fundamental to understanding cholesterol homeostasis in these cells.
Finally, two other conclusions should be emphasized. First, the molecular events whereby HDL-C ameliorates atheroma formation in the arterial wall are, presumably, very different from those specific steps involved in maintenance of physiological cholesterol balance in the cells of the extrahepatic tissues. It is not appropriate, therefore, to link these two processes together and describe them under the single term "reverse cholesterol transport". Second, if suppression of CETP activity, with the attendant elevation of HDL-C concentrations, inhibits atheroma formation without adversely affecting sterol movement from the peripheral organs to the liver, then this finding strengthens the theoretical basis for using inhibitors of CETP in humans to alter the rate of atheroma formation. 
